Chronic
neuropathic pain has demonstrated that coexisting
psychiatric disorders are associated with disability and poorer treatment outcomes. Hyperpolarization-activated
cyclic nucleotide-gated (HCN, Ih) channels play a major role in
pain via hyperexcitability and facilitation of ectopic firing in neurons. Neuronal hyperexcitability contributes to
pain maintenance and anxiety/depression.
GABA-mediated inhibitory postsynaptic neurotransmission in the brain is impaired in the pathophysiology of chronic
neuropathic pain with comorbidity
mood disorders. Currently, interaction of HCN channels and GABAergic synaptic transmission inhibition in
neuropathic pain and the associated comorbidity anxiety/depression mechanism remains relatively unknown. To address this, the HCN channel inhibitor,
ZD7288, was administrated to Wistar Kyoto (WKY) rats after spared nerve injury (SNI). Our findings show that intracerebroventricular injection of
ZD7288 concurrently attenuates co-existing nociceptive and depression-like behaviors, and increases glutamicacid
decarboxylase (GAD67/65) expression and
GABA levels in the hippocampus and thalamus with High-performance liquid chromatography technique. It suggests that inhibition of HCN channels is likely to decrease the hyperexcitability of neurons in rat SNI and improve the level of
GABA. Further, HCN channel may offer a new strategy to alleviate both
neuropathic pain and comorbidity for depression.